A multigravid client at 32 weeks who has had prior hemolytic disease of the newborn should have frequent antibody titer evaluations obtained from which source?

A multigravid client at 32 weeks who has had prior hemolytic disease of the newborn should have frequent antibody titer evaluations obtained from which source?

• A. Maternal blood
• B. Cord blood
• C. Fetal blood
• D. Amniotic fluid

Answer: (A)

When maternal alloantibodies are capable of attacking fetal red cells, the best way to gauge fetal risk is to measure the antibodies where they originate and circulate: the mother's blood. Recurrent or rising antibody titers in maternal serum indicate increasing likelihood of fetal hemolysis, so serial testing of the mother guides monitoring and timing of interventions, such as enhanced fetal surveillance. Cord blood and fetal blood would reflect the fetus’s status after exposure or after birth and require invasive sampling, which is not used for routine titration to assess risk. Amniotic fluid testing has historical utility for assessing fetal anemia indirectly but does not measure antibody levels. Therefore, obtaining frequent antibody titers from maternal blood is the standard approach in this scenario.

When maternal alloantibodies are capable of attacking fetal red cells, the best way to gauge fetal risk is to measure the antibodies where they originate and circulate: the mother's blood. Recurrent or rising antibody titers in maternal serum indicate increasing likelihood of fetal hemolysis, so serial testing of the mother guides monitoring and timing of interventions, such as enhanced fetal surveillance.

Cord blood and fetal blood would reflect the fetus’s status after exposure or after birth and require invasive sampling, which is not used for routine titration to assess risk. Amniotic fluid testing has historical utility for assessing fetal anemia indirectly but does not measure antibody levels. Therefore, obtaining frequent antibody titers from maternal blood is the standard approach in this scenario.